Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
about
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentCombined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.Ipilimumab in the treatment of advanced melanoma - a clinical update.New Translational Research in the Medical Management of Orbital Melanoma.Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trialsCorrelation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Ipilimumab in melanoma.MicroRNAs role as potential biomarkers and key regulators in melanoma.Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.Targeting protein kinase-b3 (akt3) signaling in melanoma.The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.What have we learned from cancer immunotherapy in the last 3 years?Increased treatment-related toxicity subsequent to an anti-PD-1 agent.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach.The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary MalignanciesCombination therapies in advanced melanomaWhere to start with systemic melanoma therapy?Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
P2860
Q26775546-4988B668-DD28-498F-89CC-1923F83CF057Q26796309-C45B81A8-62C1-44BE-8DD6-E888EDBA0844Q26996518-D82D74BF-0BB8-40E7-A24C-1DDFB1A33626Q27022789-695DFB97-97BE-44BC-9F57-583F850CB6B0Q33433902-538222DA-3CC5-434D-99B5-87F8A1B21544Q34667825-7F5278DF-D750-4F57-9BA6-0F3469872168Q35861663-68140B1A-4053-4547-BF30-A17D8C38A40AQ36343040-692BD2F4-FC9E-42DF-9AD7-32EEDC01BC23Q36400145-87ABCEE7-3A0E-45BC-8FE0-89CE22F62D33Q36815383-E99DB98F-AF1F-4F0F-952D-FDAFD1712796Q36821164-1A2AF0EB-BAFD-4AF8-8AF4-537C0B0663A7Q38233339-AB981237-FE42-429B-8868-3B82F42E0B05Q38245356-8F2C7F6E-B314-4749-9F85-28AB2D5367F4Q38253823-F836C343-3B5B-4470-8A4C-083125539AD5Q38766811-15405A1F-2A73-45D0-ABDE-BC2385F37943Q38770017-CC3E0A90-5088-4500-A2FD-798A5392BCE7Q38831830-C33C1F3E-D699-46D8-BC39-16A750B4CBF5Q38839130-6AB51A14-1B34-4BC3-B424-4DE9DFF44A3CQ38849629-FCB1B57F-6077-4D51-BB21-1F4BA9ADF351Q38856722-4DAE0333-1F30-4C23-A87E-BD126B81B968Q38893697-7DA642ED-CC8A-41B3-9DFD-CFEF88D17C37Q38937088-5ECD344F-C60A-49BA-BDE8-177541FB085CQ39069585-8E318820-8B06-4715-BE59-6EE84F10E655Q39071313-2BB515E9-1233-40D9-97AC-8005A98BE9C9Q39074281-23E64192-E6B1-480E-8DFF-6DA3CA8479C3Q39341329-98DB0429-3270-4278-8B35-C0DBFB2F8E17Q39570689-FBCD0074-145A-4E47-8FD2-CE03E94A52CFQ40065733-57CA8682-4BAD-4848-B475-CC367C18915EQ42207955-D9370693-C43C-4A56-826A-B2C1FA89DDAFQ43147493-C5416979-BC7C-49FF-ABFB-139F6E8BB7C7Q47268734-914E17C3-27C0-43A6-92A8-3C2D745C46EBQ47847652-62F4DE9F-3F64-4CAE-A0D4-14AEC5E94BB2Q52582484-C2D54BCF-7046-4915-8AB4-96E949AA9648Q54196202-0E66AB41-765F-4347-8155-E158435E6DA5Q55206910-4AE41AA4-8FCF-4A8F-89A6-815F13E2503CQ55517953-8603E00A-D831-46A4-9A2D-5E5E59F482E0Q56896166-409D3A2B-8BE5-43C6-B6AE-AF8320DC7F86Q56896764-794CDD10-51C6-4021-BEF5-1D92DC99C143Q56896779-64BD7135-0451-428C-94EC-7922D4281C1DQ58547833-EA49E94A-2A10-4108-BBB1-548EF8A1C908
P2860
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sequential treatment with ipil ...... mumab expanded access program.
@ast
Sequential treatment with ipil ...... mumab expanded access program.
@en
type
label
Sequential treatment with ipil ...... mumab expanded access program.
@ast
Sequential treatment with ipil ...... mumab expanded access program.
@en
prefLabel
Sequential treatment with ipil ...... mumab expanded access program.
@ast
Sequential treatment with ipil ...... mumab expanded access program.
@en
P2093
P2860
P50
P1433
P1476
Sequential treatment with ipil ...... mumab expanded access program.
@en
P2093
Ester Simeone
Fabrizio Carnevale-Schianca
Francesco Cognetti
Francesco de Rosa
Gaetana Rinaldi
Gian Carlo Antonini Cappellini
Luca Galli
Maria Grazia Bernengo
Mario Mandalà
Michele Guida
P2860
P304
P356
10.3109/07357907.2014.885984
P50
P577
2014-01-31T00:00:00Z